Cargando…

Curcumin-meropenem synergy in carbapenem resistant Klebsiella pneumoniae curcumin-meropenem synergy

BACKGROUND AND OBJECTIVES: The frequency of multiple resistant bacterial infections, including carbapenems, is increasing worldwide. As the decrease in treatment options causes difficulties in treatment, interest in new antimicrobials is increasing. One of the promising natural ingredients is curcum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gülen, Dumrul, Şafak, Birol, Erdal, Berna, Günaydın, Betül
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tehran University of Medical Sciences 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416589/ https://www.ncbi.nlm.nih.gov/pubmed/34540173 http://dx.doi.org/10.18502/ijm.v13i3.6397

Ejemplares similares

In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant Acinetobacter baumannii
por: Abdul-Mutakabbir, Jacinda C., et al.
Publicado: (2021)

Three Dimensional Checkerboard Synergy Analysis of Colistin, Meropenem, Tigecycline against Multidrug-Resistant Clinical Klebsiella pneumonia Isolates
por: Stein, Claudia, et al.
Publicado: (2015)

2746. Assessment of in vitro synergy between Piperacillin-Tazobactam-Meropenem and Imipenem-Meropenem against OXA-48 Producing Klebsiella pneumoniae Using Time-Kill Assays
por: Demir, Mervenur, et al.
Publicado: (2023)

Impact of meropenem on Klebsiella pneumoniae metabolism
por: Foschi, Claudio, et al.
Publicado: (2018)

1292. Evaluation of Synergy with Piperacillin/Tazobactam plus Meropenem Against Carbapenemase-Producing Klebsiella pneumoniae and Enterobacter cloacae Using ETEST
por: Ashcraft, Deborah S, et al.
Publicado: (2021)

Synergetic Effects of Combined Treatment of Colistin With Meropenem or Amikacin on Carbapenem-Resistant Klebsiella pneumoniae in vitro
por: Yu, Lan, et al.
Publicado: (2019)

Clinical Outcomes and Safety of Meropenem–Colistin versus Meropenem–Tigecycline in Patients with Carbapenem-Resistant Acinetobacter baumannii Pneumonia
por: Park, Jae-Min, et al.
Publicado: (2021)

In vitro evaluation of antibiotic synergy for carbapenem-resistant Klebsiella pneumoniae clinical isolates
por: Goel, Anku, et al.
Publicado: (2021)

Synergistic activity of fosfomycin–meropenem and fosfomycin–colistin against carbapenem resistant Klebsiella pneumoniae: an in vitro evidence
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2020)

Mutations in ompK36 differentially impact in vitro synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing Klebsiella pneumoniae
por: Rogers, Tara M, et al.
Publicado: (2023)

1114. Exploring bactericidal activity and emergence of resistance for carbapenem-resistant Enterobacterales (CRE) with and without Klebsiella pneumoniae carbapenemase (KPC) treated with optimized meropenem (MEM) and meropenem-vaborbactam (MEV) exposures
por: Squires, Kevin M, et al.
Publicado: (2023)

Galactose-Clicked Curcumin-Mediated Reversal of Meropenem Resistance among Klebsiella pneumoniae by Targeting Its Carbapenemases and the AcrAB-TolC Efflux System
por: Yadav, Shivangi, et al.
Publicado: (2021)

Assessment of In-Vitro Synergy of Fosfomycin with Meropenem, Amikacin and Tigecycline in Whole Genome Sequenced Extended and Pan Drug Resistant Klebsiella Pneumoniae: Exploring A Colistin Sparing Protocol
por: AL-Quraini, Manawr, et al.
Publicado: (2022)

Fluorescence Microscopy: Determination of Meropenem Activity against Klebsiella pneumoniae
por: Alieva, Kamilla N., et al.
Publicado: (2023)

Synergy effect of meropenem-based combinations against Acinetobacter baumannii: a systematic review and meta-analysis
por: Jiang, Zhihui, et al.
Publicado: (2018)

The First Case of Septicemia Caused by Imipenem-Susceptible, Meropenem-Resistant Klebsiella pneumoniae
por: Kayama, Shizuo, et al.
Publicado: (2013)

1597. Ceftolozane-Tazobactam and Meropenem Synergy Testing Against Multi-Drug and Extensively-Drug Resistant Pseudomonas aeruginosa
por: Chua, Mary Francine P, et al.
Publicado: (2020)

421. In vitro and in vivo synergistic antimicrobial activities of the combinations of meropenem, colistin, tigecycline, and ceftolozane/tazobactam against carbapenem-resistant Klebsiella pneumoniae
por: Yoon, Young Kyung, et al.
Publicado: (2022)

2183. Porin Mutations Potentiate the in Vitro Synergy of Meropenem-Vaborbactam (MVB), but not Ceftazidime-Avibactam (CZA) in Combination with Other Antibiotics against KPC-producing Klebsiella Pneumoniae (KPC-Kp)
por: Rogers, Tara M, et al.
Publicado: (2023)

Synergistic Activity of Equol and Meropenem against Carbapenem-Resistant Escherichia coli
por: Kim, Hye-Rim, et al.
Publicado: (2021)

The Place of Meropenem–Vaborbactam in the Management of Carbapenem-Resistant Gram-Negative Infections
por: Chopra, Teena
Publicado: (2021)

1542. The Evaluation of the In Vitro Synergy of Colistin in Combination with Meropenem and Tigecycline against 50 Multi-Drug-resistant Acinetobacter baumannii strains
por: Abdul-Mutakabbir, Jacinda, et al.
Publicado: (2019)

610. Meropenem-vaborbactam (MV) In Vitro Activity Against Carbapenem-Resistant Klebsiella pneumoniae (CRKP) Isolates with Outer Membrane Porin Gene Mutations
por: Yasmin, Mohamad, et al.
Publicado: (2019)

Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae
por: Sun, Dongxu, et al.
Publicado: (2017)

A case report of brain abscess caused by carbapenem-resistant Klebsiella pneumoniae
por: Tunckale, Tamer, et al.
Publicado: (2023)

Comparison of in vitro activities of meropenem productions on Klebsiella pneumoniae isolated from hospitalized patients
por: Akhi, Mohammad Taghi, et al.
Publicado: (2014)

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae
por: Petty, Lindsay A, et al.
Publicado: (2018)

Outbreak report of polymyxin-carbapenem-resistant Klebsiella pneumoniae causing untreatable infections evidenced by synergy tests and bacterial genomes
por: Gomes, Marisa Zenaide Ribeiro, et al.
Publicado: (2023)

Prediction of Minimal Inhibitory Concentration of Meropenem Against Klebsiella pneumoniae Using Metagenomic Data
por: Tan, Rundong, et al.
Publicado: (2021)

1618. Meropenem-vaborbactam vs standard of care for multidrug resistant carbapenem-resistant Enterobacteriaceae
por: Misikir, Helina, et al.
Publicado: (2020)

Antibacterial synergy of curcumin with antibiotics against biofilm producing clinical bacterial isolates
por: Kali, Arunava, et al.
Publicado: (2016)

Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study
por: Tumbarello, Mario, et al.
Publicado: (2022)

Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Northern Italy, 2018
por: Gaibani, Paolo, et al.
Publicado: (2021)

Bactericidal efficacy of meropenem in combination with cefmetazole against IMP-producing carbapenem-resistant Enterobacteriaceae
por: Abe, Ryuichiro, et al.
Publicado: (2019)

Administration of meropenem for the treatment of ventilator-associated pneumonia
por: Zolotukhin, K, et al.
Publicado: (2007)

Efficacy of tigecycline, polymyxin, gentamicin, meropenem and associations in experimental Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae non-lethal sepsis
por: Toledo, Paula Virginia Michelon, et al.
Publicado: (2014)

Molecular Nanomachines Disrupt Bacterial Cell Wall, Increasing Sensitivity of Extensively Drug-Resistant Klebsiella pneumoniae to Meropenem
por: Galbadage, Thushara, et al.
Publicado: (2019)

Use of Next Generation Sequencing and Synergy Susceptibility Testing in Diagnosis and Treatment of Carbapenem-Resistant Klebsiella pneumoniae Blood Stream Infection
por: Yu, Yuetian, et al.
Publicado: (2018)

Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections
por: Bhowmick, Tanaya, et al.
Publicado: (2020)

Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-Resistant Enterobacterales in Egypt: A Cross-Sectional Study
por: Shrief, Raghdaa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_55kgrc41rdaiqv0d79plbc7mcm